Taken together, our results demonstrate, that inhibition of DDX3 expression by using doxorubicin can be used asan ideal drug candidate to treat DDX3 associated cancer disorder by interacting with unique amino acid residues (Thr 198) andcommon amino acid residues (Tyr 200 and Thr 201). This evidence concerns the gene DDX3X and cancer.